Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$139.68 USD

139.68
634,142

+1.96 (1.42%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $139.70 +0.02 (0.01%) 6:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.

New Strong Buy Stocks for March 14th

IMMR, NVR, SKWD, DVA and APAM have been added to the Zacks Rank #1 (Strong Buy) List on March 14, 2024.

Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care

Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.

Best Value Stocks to Buy for March 14th

IMXI, SKWD and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 14, 2024.

AMN Healthcare (AMN) Expands Capabilities of ShiftWise Flex

AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.

Philips (PHG), AWS Unite to Scale Digital Pathology Solutions

Philips (PHG) collaborates with Amazon Web Services to boost cloud-based pathology solutions. It will enable pathology laboratories to use digital processes to improve analytical capabilities.

PacBio's (PACB) New Panel to Aid Its Clinical Research Solution

PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.

Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership

Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up

Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Philips (PHG) Aids Personal Health Business With New Campaign

Philips (PHG) launches #ShareTheCare brand positioning campaign for Philips Avent, bolstering the Personal Health segment.

ClearPoint's (CLPT) Prism System Favored by Latest Study

ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.

Here's Why You Should Retain BD (BDX) to Your Portfolio

BD's (BDX) slew of product launches raises optimism about the stock.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.

Bruker (BRKR) Announces Advanced timsTOF Solutions at US HUPO

Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.

GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response

GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.

Thermo Fisher (TMO) Unveils CorEvitas Clinical Registry in GPP

Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.

Cardinal Health (CAH) Hits 52-Week High: What's Driving It?

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Cigna (CI) Unveils Updated Long-Term Growth Targets & Solutions

Cigna (CI) currently estimates long-term average annual adjusted EPS growth within 10-14%. It also came up with new solutions to better manage the rising GLP-1 costs and expand behavioral care.

Should Value Investors Buy DaVita (DVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System

DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.

Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone

Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.